RE:RE:4th quarter fiscal year end 2022 conference call on May 1st All the news is already baked in, ajustments and lower revenues for 2021-2022. My guess is $25Mill will be corrected on the balance sheets. Plus the exit out of Cal, Org, Col which cost them $50Mil to make $5Mill, those markets continue to lag, the new capital will be better spent to expand their new products, automation and M&As in new states plus the EU. 19mths away from the U.S. election, Biden is on the ropes to get something done on cannabis. Potential uplistings for MSOs on the TSX or the CSE Tier 1 are adding major pressure to the U.S. NYSE/NASDAQ listings to bring in MSOs, no one wants to miss out on the cannabis boom. No point getting into all the other positive things going on... CURA is @ a pre IPO position, retail are in a advantageous seat which is an anomaly in a 30Billion U.S. Market expected to hit $50Billion by 2028. My guess is continued selling presure from shorts to keep out retail as they build their positions. MSOs can not be held back for to much longer. Continued growth Q after Q, new states joining and EU, German and UK expanssion continues. No ones is going to bet the farm as most have been burned and will wait to see how things play out. Place your bets